IL158201A0 - Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine - Google Patents

Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Info

Publication number
IL158201A0
IL158201A0 IL15820102A IL15820102A IL158201A0 IL 158201 A0 IL158201 A0 IL 158201A0 IL 15820102 A IL15820102 A IL 15820102A IL 15820102 A IL15820102 A IL 15820102A IL 158201 A0 IL158201 A0 IL 158201A0
Authority
IL
Israel
Prior art keywords
cox
inhibitor
drug
solvent
pharmaceutical composition
Prior art date
Application number
IL15820102A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL158201A0 publication Critical patent/IL158201A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL15820102A 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine IL158201A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (1)

Publication Number Publication Date
IL158201A0 true IL158201A0 (en) 2004-05-12

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15820102A IL158201A0 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Country Status (18)

Country Link
US (1) US20030105141A1 (https=)
EP (1) EP1379279A1 (https=)
JP (1) JP2004530669A (https=)
KR (1) KR20040018355A (https=)
CN (1) CN1516601A (https=)
AR (1) AR033221A1 (https=)
AU (1) AU2002305175B2 (https=)
BR (1) BR0208994A (https=)
CA (1) CA2444220A1 (https=)
CZ (1) CZ20032792A3 (https=)
EA (1) EA008103B1 (https=)
IL (1) IL158201A0 (https=)
MX (1) MXPA03009411A (https=)
NO (1) NO20034629L (https=)
NZ (1) NZ528741A (https=)
PE (1) PE20021145A1 (https=)
PL (1) PL364524A1 (https=)
WO (1) WO2002083177A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
SI2279729T1 (sl) * 2003-07-17 2016-10-28 Banner Life Sciences, LLC Pripravki z nadziranim sproščanjem
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MX2007009888A (es) * 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
CA2627292C (en) * 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US8999381B2 (en) * 2007-09-27 2015-04-07 Wockhardt Ltd. Self-emulsifying pharmaceutical compositions of rhein or diacerein
MX2011005643A (es) * 2008-12-03 2011-09-27 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JO3587B1 (ar) * 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
WO2013058303A1 (ja) * 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
CN109477010B (zh) 2016-07-05 2021-07-23 戈登可再生能源有限公司 用于将废弃塑料转化成燃料的系统和工艺
US12213510B2 (en) 2019-09-11 2025-02-04 Nicoventures Trading Limited Pouched products with enhanced flavor stability
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69422306T4 (de) * 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
CA2301304A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
AU2001282886A1 (en) * 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain

Also Published As

Publication number Publication date
CA2444220A1 (en) 2002-10-24
NO20034629D0 (no) 2003-10-16
EP1379279A1 (en) 2004-01-14
PL364524A1 (en) 2004-12-13
CN1516601A (zh) 2004-07-28
AR033221A1 (es) 2003-12-10
KR20040018355A (ko) 2004-03-03
WO2002083177A1 (en) 2002-10-24
JP2004530669A (ja) 2004-10-07
EA008103B1 (ru) 2007-04-27
CZ20032792A3 (cs) 2004-04-14
AU2002305175B2 (en) 2007-07-12
PE20021145A1 (es) 2003-01-16
BR0208994A (pt) 2004-04-27
NZ528741A (en) 2005-09-30
US20030105141A1 (en) 2003-06-05
NO20034629L (no) 2003-12-10
EA200301019A1 (ru) 2004-06-24
MXPA03009411A (es) 2004-01-29

Similar Documents

Publication Publication Date Title
IL158201A0 (en) Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
IL216686A (en) Ritonavir-containing drug solution and organic solvent containing a mixture of long fatty acids and water
ITMI20021660A1 (it) Sistema di somministrazione di farmaco bioadesivo
CY2013023I1 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
NO20031784D0 (no) Heteroarylalkylpiperazinderivater som fettsyre- oksydasjonsinhibitorer
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
AU2001288998A1 (en) Pharmaceutical formulations containing a non-steroidal antiinflammatory drug anda proton pump inhibitor
NO20040564L (no) Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
IL208891A0 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
CY1114210T1 (el) Απο του στοματος μορφη δοσολογιας περιλαμβανουσα αναστολεα pde 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
AU2003296897A8 (en) Pharmaceutical formulations of camptothecine derivatives
AR079399A2 (es) Procedimientos para preparar bifenazato
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
HUP0303694A3 (en) Aza-amino acid derivatives and pharmaceutical
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
HUP0302534A3 (en) Preparation of mandelic acid derivatives
GB2398005B (en) Orally administrable pharmaceutical formulation
IS8232A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
ATE349459T1 (de) Polymorph b eines bekannten thiophencarbonsäuredodecahydrocyclopenta(a)phen ntrenylesters